Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-18

With regard to the intrinsic value, I keep returning to the fact that they have a product approved in Europe that seems to work in a condition with few options. As a form of radiotherapy it’s much less problematic and higher dose than external beam radiotherapy.

I know things could be better, approvals extended to Folfirinox, RCT evidence for reimbursement etc etc. But they have an actual marketable product that seems to reduce the size of the cancer. So many other companies have nothing yet and yet have much higher market value.